Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.
Loading...
Embargo End Date
ICR Authors
Authors
Ray-Coquard, I
Rizzo, E
Blay, JY
Casali, P
Judson, I
Hansen, AK
Lindner, LH
Dei Tos, AP
Gelderblom, H
Marreaud, S
Litière, S
Rutkowski, P
Hohenberger, P
Gronchi, A
van der Graaf, WT
Rizzo, E
Blay, JY
Casali, P
Judson, I
Hansen, AK
Lindner, LH
Dei Tos, AP
Gelderblom, H
Marreaud, S
Litière, S
Rutkowski, P
Hohenberger, P
Gronchi, A
van der Graaf, WT
Document Type
Journal Article
Date
2016-07-01
Date Accepted
2016-05-15
Abstract
OBJECTIVE: UtS are a group of uncommon tumors representing 1% of malignant neoplasms of the female genital tract, and 7% of sarcomas. The objective of this study was to evaluate the factors associated with the clinical behavior UtS. METHODS: Information on 269 patients with advanced or metastatic first line UtS treated by chemotherapy was available in a database containing information on 3270 patients with advanced soft tissue sarcomas (STS) entered in EORTC-STBSG clinical trials between 1977 and 2010. The chemotherapy was aggregated in 4 categories: anthracyclines alone, ifosfamide alone, the combination of doxorubicin and ifosfamide, and CYVADIC. RESULTS: Among the 269 UtS pts, there were 231 deaths (median OS 10.4months, 95% CI: 9.1-11.9) and 257 progressions and/or deaths (median PFS 4.1months, 95% CI: 3.5-4.9). Multivariate analyses reported PS (p<0.001) only to be a statistically significant prognostic factor for OS in UtS; for PFS, LMS histology (p=0.025) is associated with a better outcome. There was no relationship between the 4 groups of chemotherapy regimens and impact on clinical outcomes. Histological subtype was significantly correlated with response to chemotherapy (RR: LMS 19% vs other 33%, p=0.026). Ifosfamide single agent yielded only 5% of RR. CONCLUSIONS: Clearly, UtS are very aggressive neoplasms with poor outcome when treated with chemotherapy consisting of anthracyclines with or without ifosfamide or cyclophosphamide. New strategies are urgently needed.
Citation
Gynecologic oncology, 2016, 142 (1), pp. 95 - 101
Rights
Source Title
Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
ISSN
0090-8258
eISSN
1095-6859
Collections
Research Team
Clinical and Translational Sarcoma
Sarcoma Clinical Trials
Sarcoma Clinical Trials